Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label study of KLT-1101 alone or with toripalimab in melanoma and other solid tumors
CTR20234102Phase 2Active
- Sponsor
- Zhuhai Kanglitai Pharmaceutical
- Start
- Sep 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of KLT-1101 in melanoma, Nonhematologic neoplasms, sponsored by Zhuhai Kanglitai Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
KLT-1101
03
Conditions
melanomaNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20234102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234102.